Annual EBITDA
$23.57 M
+$47.11 M+200.16%
December 31, 2023
Summary
- As of February 7, 2025, CTNM annual EBITDA is $23.57 million, with the most recent change of +$47.11 million (+200.16%) on December 31, 2023.
- During the last 3 years, CTNM annual EBITDA has risen by +$51.92 million (+183.17%).
- CTNM annual EBITDA is now at all-time high.
Performance
CTNM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$10.21 M
-$1.26 M-14.04%
September 30, 2024
Summary
- As of February 7, 2025, CTNM quarterly EBITDA is -$10.21 million, with the most recent change of -$1.26 million (-14.04%) on September 30, 2024.
- Over the past year, CTNM quarterly EBITDA has dropped by -$2.31 million (-29.29%).
- CTNM quarterly EBITDA is now -124.04% below its all-time high of $42.45 million, reached on June 1, 2023.
Performance
CTNM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$35.40 M
-$3.88 M-12.30%
September 30, 2024
Summary
- As of February 7, 2025, CTNM TTM EBITDA is -$35.40 million, with the most recent change of -$3.88 million (-12.30%) on September 30, 2024.
- Over the past year, CTNM TTM EBITDA has dropped by -$58.98 million (-250.18%).
- CTNM TTM EBITDA is now -216.22% below its all-time high of $30.46 million, reached on June 1, 2023.
Performance
CTNM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CTNM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +200.2% | -29.3% | -250.2% |
| 3 y3 years | +183.2% | -39.2% | -383.0% |
| 5 y5 years | +183.2% | -39.2% | -383.0% |
CTNM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +183.2% | -124.0% | at low | -216.2% | at low |
| 5 y | 5-year | at high | +183.2% | -124.0% | at low | -216.2% | at low |
| alltime | all time | at high | +183.2% | -124.0% | at low | -216.2% | at low |
Contineum Therapeutics Class A EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$10.21 M(+14.0%) | -$35.40 M(+12.3%) |
| Jun 2024 | - | -$8.95 M(+7.1%) | -$31.52 M(-258.6%) |
| Mar 2024 | - | -$8.36 M(+5.9%) | $19.88 M(-15.7%) |
| Dec 2023 | $23.57 M | -$7.89 M(+24.8%) | $23.57 M(-2.3%) |
| Sep 2023 | - | -$6.33 M(-114.9%) | $24.14 M(-20.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | $42.45 M(-1011.2%) | $30.46 M(-354.1%) |
| Mar 2023 | - | -$4.66 M(-36.4%) | -$11.99 M(+63.6%) |
| Dec 2022 | -$23.54 M(-17.0%) | - | - |
| Dec 2022 | - | -$7.33 M | -$7.33 M |
| Dec 2021 | -$28.34 M | - | - |
FAQ
- What is Contineum Therapeutics Class A annual EBITDA?
- What is the all time high annual EBITDA for Contineum Therapeutics Class A?
- What is Contineum Therapeutics Class A annual EBITDA year-on-year change?
- What is Contineum Therapeutics Class A quarterly EBITDA?
- What is the all time high quarterly EBITDA for Contineum Therapeutics Class A?
- What is Contineum Therapeutics Class A quarterly EBITDA year-on-year change?
- What is Contineum Therapeutics Class A TTM EBITDA?
- What is the all time high TTM EBITDA for Contineum Therapeutics Class A?
- What is Contineum Therapeutics Class A TTM EBITDA year-on-year change?
What is Contineum Therapeutics Class A annual EBITDA?
The current annual EBITDA of CTNM is $23.57 M
What is the all time high annual EBITDA for Contineum Therapeutics Class A?
Contineum Therapeutics Class A all-time high annual EBITDA is $23.57 M
What is Contineum Therapeutics Class A annual EBITDA year-on-year change?
Over the past year, CTNM annual EBITDA has changed by +$47.11 M (+200.16%)
What is Contineum Therapeutics Class A quarterly EBITDA?
The current quarterly EBITDA of CTNM is -$10.21 M
What is the all time high quarterly EBITDA for Contineum Therapeutics Class A?
Contineum Therapeutics Class A all-time high quarterly EBITDA is $42.45 M
What is Contineum Therapeutics Class A quarterly EBITDA year-on-year change?
Over the past year, CTNM quarterly EBITDA has changed by -$2.31 M (-29.29%)
What is Contineum Therapeutics Class A TTM EBITDA?
The current TTM EBITDA of CTNM is -$35.40 M
What is the all time high TTM EBITDA for Contineum Therapeutics Class A?
Contineum Therapeutics Class A all-time high TTM EBITDA is $30.46 M
What is Contineum Therapeutics Class A TTM EBITDA year-on-year change?
Over the past year, CTNM TTM EBITDA has changed by -$58.98 M (-250.18%)